Eli Lilly and GlaxoSmithKline are both pharma royalty. Which stock is the better buy right now?
News & Analysis: Eli Lilly and Company
AbbVie and Eli Lilly are two rock-solid dividend plays, but only one is a buy right now.
Pharmaceutical companies are suddenly eager to lower drug prices.
Find out which iconic pharmaceutical giant is the better stock pick at the moment.
See how the streamlined pharmaceutical company stacks up to the healthcare conglomerate.
One of these is paying a more generous dividend, but is it right for your portfolio?
A gleaming fourth-quarter earnings report made it a lot easier to forget about a high-profile clinical trial failure.
LLY earnings call for the period ending December 31, 2018.
The big pharma company made all the right moves in 2018.
The biopharma delivered the goods with its drug pipeline, scored marketing approval for its lead drug candidate, and agreed to be acquired for $8 billion.